A multicentre phase I/II trial to investigate the efficacy, biological activity, safety and tolerability of IPH 1101 and low dose interleukin-2 in combination with rituximab [Mabthera/Rituxan] in patients with follicular non-Hodgkin's lymphoma relapsing after at least one prior rituximab-containing course of treatment.

Trial Profile

A multicentre phase I/II trial to investigate the efficacy, biological activity, safety and tolerability of IPH 1101 and low dose interleukin-2 in combination with rituximab [Mabthera/Rituxan] in patients with follicular non-Hodgkin's lymphoma relapsing after at least one prior rituximab-containing course of treatment.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs IPH 1101 (Primary) ; Aldesleukin; Rituximab
  • Indications Follicular lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Innate Pharma
  • Most Recent Events

    • 14 Jun 2010 Status changed from recruiting to active, no longer recruiting.
    • 14 Jun 2010 Final data of this trial has been presented at the Annual European Hematology Association (EHA) Meeting 2010, according to an Innate Pharma media release.
    • 03 Jun 2010 Final data will be the subject of an oral presentation by Pr Jean-Francois Rossi at the Annual European Hematology Association (EHA) Meeting 2010, according to an Innate Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top